{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:31:20Z","timestamp":1768318280812,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.diagmicrobio.2019.114896","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T11:21:43Z","timestamp":1568373703000},"page":"114896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Don\u2019t mess with the machine \u2014 evaluation of fluconazole susceptibility testing for Candida glabrata using the new VITEK2 AST-YS08 card following species modification"],"prefix":"10.1016","volume":"96","author":[{"given":"Maya","family":"Korem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Geffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Amit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.riam.2016.12.002","article-title":"Comparison of the VITEK 2 antifungal susceptibility system with Etest using clinical isolates of Candida species","volume":"34","author":"Alfouzan","year":"2017","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0010","series-title":"M60","article-title":"Performance standards for antifungal susceptibility testing of yeasts","author":"CLSI","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0015","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1128\/JCM.02316-09","volume":"48","author":"Cuenca-Estrella","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.diagmicrobio.2012.02.001","article-title":"The changing epidemiology of healthcare-associated candidemia over three decades","volume":"73","author":"Diekema","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0025","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/jac\/dks482","article-title":"Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study","volume":"68","author":"Eschenauer","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0030","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/phar.1146","article-title":"Antifungal susceptibility testing: a primer for clinicians","volume":"32","author":"Kuper","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0035","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care\u2013associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0040","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0045","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0050","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1128\/JCM.02517-10","article-title":"Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp","volume":"49","author":"Peterson","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0055","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1128\/JCM.00937-12","article-title":"Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0060","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1128\/JCM.00403-07","article-title":"Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp","volume":"45","author":"Pfaller","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0065","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1128\/JCM.00658-14","article-title":"Multicenter evaluation of the new vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole","volume":"52","author":"Pfaller","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0070","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/JCM.01398-10","article-title":"Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)","volume":"49","author":"Pfaller","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.114896_bb0075","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1128\/JCM.02070-08","article-title":"Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata","volume":"47","author":"Posteraro","year":"2009","journal-title":"J Clin Microbiol"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319305942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319305942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:52:43Z","timestamp":1760003563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889319305942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0732889319305942"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.114896","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Don\u2019t mess with the machine \u2014 evaluation of fluconazole susceptibility testing for Candida glabrata using the new VITEK2 AST-YS08 card following species modification","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.114896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114896"}}